Buy Synergy Pharmaceuticals on FDA Approval of New Drug

By Joe Duarte • January 27, 2017

I am issuing a buy Recommendation on Synergy Pharmaceuticals (NSDQ: SGYP), a biotech company focusing in diseases and conditions of the digestive system. The company received FDA approval for its idiopathic constipation drug Trulance on January 19, 2017. The stock dipped initially but has recovered and is showing positive momentum. The constipation market is wide open which gives Synergy the potential for a blockbuster with Trulance. This is a small company and this is a dicey market, but at this point the rewards outweigh the risks. I will have more on Monday’s edition of Breakthrough Tech Weekly.

Buy SGYP up to $7. Set a sell stop at $5.

I have a position in SGYP.

Stock Talk

Comments Guidelines
M

Med

Hi Joe,
SGYP receives U.S FDA approval for the treatment of Adults with Chronic Idiopathic constipation on Jan 19th ..! The stock is being going up since..! why we didn’t the get the inf on time or a bit earlier via the insider to benefit from the stock grows..?

Cheers,

Joe Duarte

Joe Duarte

With companies such as Synergy, I’ve learned that it’s best to wait for the FDA approval and the market’s response before making a commitment. It’s been on my radar screen for a while. I’ll have more in Monday’s BTP Weekly. It is still a highly speculative company with one product that is not even on the market. The flip side is that there are 40 plus million people who may need this drug. But concept and reality aren’t always the same thing. Safety first. It’s more about the return of your money not the return on your money.

M

Med

Thx Joe for the quick feedback ..!

Add New Comments

You must be logged in to post to Stock Talk OR create an account